2P4 Stock Overview
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BioPorto A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr.0.15 |
| 52 Week High | kr.0.43 |
| 52 Week Low | kr.0.13 |
| Beta | 1.19 |
| 1 Month Change | -8.09% |
| 3 Month Change | -44.85% |
| 1 Year Change | -21.30% |
| 3 Year Change | -75.96% |
| 5 Year Change | -71.26% |
| Change since IPO | -64.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2P4 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -3.1% | -1.2% | 1.7% |
| 1Y | -21.3% | -23.0% | 2.3% |
Return vs Industry: 2P4 exceeded the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: 2P4 underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| 2P4 volatility | |
|---|---|
| 2P4 Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2P4's share price has been volatile over the past 3 months.
Volatility Over Time: 2P4's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 29 | Peter Eriksen | bioporto.com |
BioPorto A/S, an in-vitro diagnostics company, provides biomarker tools and antibodies for clinical research in Europe, North America, Asia, and internationally. It offers the neutrophil gelatinase-associated lipocalin test, a quantitative particle-enhanced turbidimetric immunoassay designed to run on automated clinical chemistry analyzers; monoclonal antibodies for scientific, pharmaceutical, and clinical research; and enzyme-linked immunosorbent assay kits, as well as generic rapid assay device for custom lateral flow assays. BioPorto A/S was incorporated in 1917 and is based in Hellerup, Denmark.
BioPorto A/S Fundamentals Summary
| 2P4 fundamental statistics | |
|---|---|
| Market cap | €62.51m |
| Earnings (TTM) | -€7.55m |
| Revenue (TTM) | €4.15m |
15.1x
P/S Ratio-8.3x
P/E RatioIs 2P4 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2P4 income statement (TTM) | |
|---|---|
| Revenue | kr.30.96m |
| Cost of Revenue | kr.10.78m |
| Gross Profit | kr.20.18m |
| Other Expenses | kr.76.51m |
| Earnings | -kr.56.33m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 08, 2024
| Earnings per share (EPS) | -0.15 |
| Gross Margin | 65.19% |
| Net Profit Margin | -181.95% |
| Debt/Equity Ratio | 0% |
How did 2P4 perform over the long term?
See historical performance and comparison